Evidence map›Paper›PMID 37835567›Full record

ArticleCancers2023

Blood Immune Cells as Biomarkers in Long-Term Surviving Patients with Advanced Non-Small-Cell Lung Cancer Undergoing a Combined Immune/Chemotherapy.

Miriam Möller, Wolfgang Schütte, Steffi Turzer, Barbara Seliger, Dagmar Riemann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Miriam MöllerClinic of Internal Medicine, Hospital Martha-Maria Halle-Dölau, 06120 Halle, Germany.ORCID 0000-0002-0948-9469
Wolfgang SchütteClinic of Internal Medicine, Hospital Martha-Maria Halle-Dölau, 06120 Halle, Germany.
Steffi TurzerInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle, Germany.
Barbara SeligerInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle, Germany.ORCID 0000-0002-5544-4958
Dagmar RiemannInstitute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle, Germany.ORCID 0000-0002-7989-6262
Martha-Maria Hospital · DEMartin Luther University Halle-Wittenberg · DEMedizinische Hochschule Brandenburg Theodor Fontane · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An important challenge remains in identifying the baseline characteristics of cancer patients who will mostly benefit from immune checkpoint inhibitor (ICI) therapies. Furthermore, biomarkers could help in the choice of an optimal therapy duration after a primary therapy response. In this pilot study, the time courses of four different immune cell parameters were followed in 12 patients with advanced non-small-cell lung cancer (NSCLC) undergoing ICI therapy combined with chemotherapy and surviving at least 12 months. Blood was collected at the time point of the first and third antibody administration, as well as after 12 months of patients' survival. Using multi-color flow cytometry, two suppressive markers (neutrophil/lymphocyte ratio (NLR) and the frequency of circulating HLA-DR

Indexed as

biomarkersdendritic cellsHLA-DRlow monocytesimmune checkpoint blockadelong-term survivalneutrophil/lymphocyte rationon-small-cell lung cancerslan+ non-classical monocytes

Identifiers

PMID37835567
PMCPMC10572005
OpenAlexW4387454977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.